Compare iShares 1 3 Year Treasury Bond ETF (SHY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 1 3 Year Treasury Bond ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares 1 3 Year Treasury Bond ETF trades at $81.34 (market cap $26.87B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: iShares 1 3 Year Treasury Bond ETF is far larger — about 3.6× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 1 3 Year Treasury Bond ETF for 64 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SHY | SYRE | |
|---|---|---|
Market Cap | $26.87B | $7.52B |
Volume | 3,180,822 | 1,441,031 |
Sector | Fixed Income | Health |
52-Week High | $83.18 | $108.92 |
52-Week Low | $81.05 | $22.18 |
Typical Hold Time | 64 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHY, a US stock, trades at $81.19 with minimal daily movement, reflecting stability amid broader bond market volatility. Technical indicators show a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent dividend actions provide income, but key financial ratios are unavailable. The stock's price action is tightly range-bound with support and resistance near $81.
The outlook for SHY is cautious due to bearish technical signals and a lack of fundamental data. Risks include interest rate sensitivity and macroeconomic pressures from rising bond yields. Investment opportunities may lie in its dividend yield if fundamentals strengthen, but current sentiment and technicals suggest limited near-term upside.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
